Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

NNASDAQ:ENSC
0.41
USD
-0.01
(-2.13%)
-1.91EPS
4.46MMarket Cap
Apr 01Next Earn

Total Valuation

USD

As of June 30, 2026, Ensysce Biosciences, Inc. carries a market capitalization of 4.46M, placing it among publicly traded companies globally. Its enterprise value stands at 3.65M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.46M
Enterprise Value3.65M

Important Dates

Ensysce Biosciences, Inc.'s next confirmed earnings release is scheduled for April 1, 2027.

Earnings Date4/1/2027

Share Statistics

As of June 30, 2026, Ensysce Biosciences, Inc. has 15.37M shares outstanding.

Shares Outstanding15.37M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio-5.70
P/TBV Ratio-5.70
P/FCF Ratio-0.22
P/OCF Ratio-0.22

Financial Position

As of June 30, 2026, Ensysce Biosciences, Inc. maintains a current ratio of 0.70, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -17.72, indicating conservative leverage, while an interest coverage ratio of -790.83 demonstrates limited ability to service its debt obligations.

Current Ratio0.70
Quick Ratio0.27
Debt / Equity-17.72
Debt / EBITDA-0.02
Interest Coverage-790.83

Financial Efficiency

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -295.93, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 9.75, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-295.93
Employee Count9.75

Stock Price Statistics

USD

As of the close on November 16, 2026, Ensysce Biosciences, Inc.'s stock has declined approximately 80.12% over the past 52 weeks. The 50-day moving average sits at 0.44, while the 200-day moving average is 0.41.

52-Week Price Change-80.12%
50-Day Moving Average0.44
200-Day Moving Average0.41

Income Statement

USD

Over the twelve months ended June 30, 2026, Ensysce Biosciences, Inc. generated - - in revenue and converted that into -12.62M in net income, yielding earnings per share of -1.91. EBITDA reached -12.65M, while operating income came in at -12.66M.

Operating Income-12.66M
Pretax Income-12.62M
Net Income-12.62M
EBITDA-12.65M
EBIT-12.66M
Earnings Per Share (EPS)-1.91

Balance Sheet

USD

As of June 30, 2026, Ensysce Biosciences, Inc. holds 676,704.00 in cash and equivalents against 196,842.00 in total debt, resulting in a net debt position of -479,862.00. Total book value stands at -781,697.00, with working capital of -1.22M providing operational flexibility.

Cash & Cash Equivalents676,704.00
Total Debt196,842.00
Net Debt-479,862.00
Equity (Book Value)-781,697.00
Book Value Per Share-0.05
Working Capital-1.22M

Cash Flow

USD

Ensysce Biosciences, Inc. produced -8.86M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -8.86M - equivalent to -1.34 per share.

Operating Cash Flow-8.86M
Free Cash Flow-8.86M
FCF Per Share-1.34

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -461.77: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -167.06, meaning Ensysce Biosciences, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-167.06
FCF Yield-461.77

Stock Splits

Ensysce Biosciences, Inc.'s most recent stock split took place on December 6, 2024 with a 15:1 split ratio.

Last Split Date12/6/2024
Split Ratio15:1

Scores

As of June 30, 2026, Ensysce Biosciences, Inc. has an Altman Z-Score of -83.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-83.01